Evidence map›Paper›PMID 23364515›Full record

ArticleJournal of biomolecular screening2013

Identification of a small-molecule inhibitor of bacterial AraC family activators.

Jeff M Skredenske, Veerendra Koppolu, Ana Kolin, James Deng, Bria Kettle, Byron Taylor, Susan M Egan

Open access · hybridAbstract read
In one paragraph

Article in Journal of biomolecular screening, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. A high-throughput system to identify inhibitors ofProceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  4. Review
  5. The Multifaceted Activity of the VirF Regulatory Protein in theFrontiers in molecular biosciences · 2016
    Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jeff M SkredenskeDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA.
Veerendra Koppolu
Ana Kolin
James Deng
Bria Kettle
Byron Taylor
Susan M Egan
University of Kansas · US

Funding

PHARMACEUTICAL ASPECTS OF BIOTECHNOLOGY TRAININGT32GM008359 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI SIAHAAN, TERUNA J., VOLKIN, DAVID · 1989 to 2018
$5.0M
Transcription Activation at the rhaBAD OperonR01GM055099 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI EGAN, SUSAN M · 2005 to 2008
$820k
NIGMS NIH HHS R01 GM055099NIGMS NIH HHS R01GM55099NIGMS NIH HHS T32 GM008359NIGMS NIH HHS T32GM008359
6 · The paper itself

Abstract

Protein members of the AraC family of bacterial transcriptional activators have great promise as targets for the development of novel antibacterial agents. Here, we describe an in vivo high-throughput screen to identify inhibitors of the AraC family activator protein RhaS. The screen used two Escherichia coli reporter fusions: one to identify potential RhaS inhibitors and a second to eliminate nonspecific inhibitors from consideration. One compound with excellent selectivity, OSSL_051168, was chosen for further study. OSSL_051168 inhibited in vivo transcription activation by the RhaS DNA-binding domain to the same extent as the full-length protein, indicating that this domain was the target of its inhibition. Growth curves showed that OSSL_051168 did not affect bacterial cell growth at the concentrations used in this study. In vitro DNA-binding assays with purified protein suggest that OSSL_051168 inhibits DNA binding by RhaS. In addition, we found that it inhibits DNA binding by a second AraC family protein, RhaR, which shares 30% amino acid identity with RhaS. OSSL_051168 did not have a significant impact on DNA binding by the non-AraC family proteins CRP and LacI, suggesting that the inhibition is likely specific for RhaS, RhaR, and possibly additional AraC family activator proteins.

Indexed as

Anti-Bacterial AgentsAraC Transcription FactorDNA, BacterialDose-Response Relationship, DrugDrug DiscoveryEscherichia coliEscherichia coli ProteinsGene Expression Regulation, BacterialHigh-Throughput Screening AssaysMicrobial Sensitivity TestsModels, BiologicalMultigene FamilyProtein BindingQuinolinesSmall Molecule LibrariesTrans-Activators1-butyl-4-nitromethyl-3-quinolin-2-yl-4H-quinolineAnti-Bacterial AgentsAraC Transcription FactorDNA, BacterialEscherichia coli ProteinsQuinolinesRhaS protein, E coliSmall Molecule LibrariesTrans-Activatorsantibacterial agentsAraC family activatorscell-based assayshigh-throughput screeninginhibitor

Identifiers

PMID23364515
PMCPMC3663881
OpenAlexW2040000016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.